Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: Comparison of Kras Rank+/+ and Kras Rankfl/fl mouse primary pneumocytes treated with Rankl ex vivo

PROVIDER: PRJNA322267 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3548034.fastq.gz	Fastqsanger.gz
	SRR3548035.fastq.gz	Fastqsanger.gz
	SRR3548036.fastq.gz	Fastqsanger.gz
	SRR3548037.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Comparison of Kras;Rank+/+ and Kras;Rankfl/fl mouse primary pneumocytes treated with Rankl ex vivo

Project description:The transcriptional profile of Kras;Rank +/+ and Kras;Rank fl/fl mouse primary pneumocytes were determined by mRNA sequencing and uncovered differences in their molecular signatures including genes involved in cell-cell junction, mitosis, mitochondrial homeostasis, TCA cycle and respiratory electron transport

2017-12-22 | GSE81670 | GEO

Comparison of KRas;Atg5fl/+ and KRas;Atg5fl/fl pneumocytes

Project description:Primary pneumocytes from KRas;Atg5fl/+ and KRas;Atg5fl/fl littermates were cultured for 48 hours and infected with AdCre-GFP to induce expression of the KrasG12D oncogene and concomitant Atg5 deletion. The transcriptional profile of those cells was determined by mRNA sequencing and uncovered differential expression in cellular movement, inflammatory response and oxidative stress response. Comparison of transcriptomes from KRas;Atg5fl/+ and KRas;Atg5fl/fl pneumocytes

2014-01-07 | E-GEOD-48387 | biostudies-arrayexpress

Mus musculus

Project description:Comparison of KRas Atg5fl/+ and KRas Atg5fl/fl pneumocytes

| PRJNA209969 | ENA

Comparison of KRas;Atg5fl/+ and KRas;Atg5fl/fl pneumocytes

2014-01-07 | GSE48387 | GEO

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and functionally contributes to increase tumor aggressiveness

Project description:Analyses of genes expression in estrogen receptor negative, RANK positive, breast cancer orthoxenografts after in vivo treatment (4 weeks) with RANKL , RANK-Fc or denosumab.

2023-01-19 | GSE185513 | GEO

RANKL-RANK activation in mmtv-Pymt primary tumor cultures

Project description:RANKL-RANK activation in mmtv-Pymt primary tumor cultures

| PRJNA601437 | ENA

Amplification of RANK- and c-Met-mediated signaling promotes metastatic colonization

Project description:We found that RANKL, expressed by cancer cells or derived from exogenous sources, consistently induced human prostate, breast, kidney, lung and liver cancer cells to colonize or metastasize to bone in an animal model of cancer bone metastasis. RANK-mediated signaling established a premetastatic niche through a forward feedback loop by inducing RANKL and c-Met expression and downstream signaling via upregulation of master regulator transcription factors regulating EMT (Twist1, Slug, Zeb1, Zeb2), stem cells (Sox2, Myc, Oct3/4 and Nanog), neuroendocrine cells (Sox 9, HIF-1α and FoxA2) and osteomimicry (c-Myc/Max, Sox2, Sox9, HIF1α and Runx2). Abrogating RANK or its downstream signaling network, c-Myc/Max or c-Met, abolished PCa skeletal metastasis in mice. We observed that a small number of RANKL-expressing PCa cells can initiate bone and soft tissue metastases by recruiting non-tumorigenic or bystander PCa or host cells from the circulation or at metastatic sites to co-colonize bone. The recruited bystander PCa cells assume the phenotypes of RANKL-expressing PCa cells by expressing increased c-Met, phosphorylated c-Met and RANKL. RANKL expression at a single cell level in primary PCa tissues predicted disease-specific survival, reflecting the significant role of RANKL-RANK signaling in the development of lethal bone metastasis. Global gene expression analysis perturbed by RANKL in LNRANKL compared to LNNeo cells.

2014-02-06 | E-GEOD-48432 | biostudies-arrayexpress

Comparison expression data from wild-type and NFATc1-deficient osteoclasts

Project description:Genetic deletion of Nfatc1 in mice results in profound osteoclast-poor osteopetrosis, a high bone mass state caused by a lack of osteoclast activity. We hypothesized that the family of NFATc1 regulated transcripts in the osteoclast would be enriched for genes associated with osteoclast function. We used microarrays profile gene expression in wild-type and NFATc1-deficient osteoclasts generated in vitro to identify NFATc1-dependent transcripts in osteoclasts. Bone marrow macrophages from wild-type and mice with an induced deficiency of NFATc1 (NFATc1 fl/fl MxCre+ mice where NFATc1 excision was induced by polyIC treatment) were cultured ex vivo in MCSF and RANKL for 3 days. 2 biological replicates were assayed for each genotype.

2012-08-18 | E-GEOD-37219 | biostudies-arrayexpress

OPG promotes lung metastasis by blocking the RANKL-RANK-CXCL10 axis to drive NK cell paucity (CRISPR)

Project description:Metastasis is the major cause of cancer-related mortality. In the lung metastasis, monocyte-derived macrophages (Mo-macs) exhibit a complex function. However, tumor cells how to derive lung metastasis through Mo-macs remains unclear. Here we show that a tumor-secreted protein osteoprotegerin (OPG) contributes to the lung metastasis of cancer depends on the Mo-macs by an in vivo screening. OPG binds with RANKL to block the signaling between RANKL-RANK on Mo-macs. RANKL-RANK signals induce Mo-macs to secrete CXCL10, recruiting NK cells to control the lung metastasis. Increased expression of OPG in the metastases is regulated by TGF-β. Consistent with our findings, enrichment of OPG amplifications was observed in metastatic cancer patients, and increased expression of OPG was also shown in the lung metastatic sites compared with the paired primary breast cancer samples. Overall, our findings reveal a mechanism of how tumor cells promote lung metastasis via inhibiting the function of Mo-macs.

2024-12-16 | GSE260469 | GEO

OPG promotes lung metastasis by blocking the RANKL-RANK-CXCL10 axis to drive NK cell paucity

2024-12-16 | GSE259293 | GEO